LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that new data on Feraheme® (ferumoxytol) Injection for intravenous (IV) use have been accepted for presentation at the American Society of Nephrology Kidney Week meeting taking place November 8-13, 2011 in Philadelphia, PA.
